CA 72-4

CA 72-4

An immunoassay that detects tumor-associated glycoprotein 72, an antigen found on many mucin-secreting gastrointestinal cancers.
Mentioned in ?
References in periodicals archive ?
On the other hand some previous reports made this hypothesis controversial with the higher positivity rate of CEA CA 72-4 and CA 19-9 in the diffuse type of gastric cancer.
Prognostic significance of CEA CA 19-9and CA 72-4 preoperative serum levels in gastric carcinoma.
Cramer reported that the top-performing marker was CA 125, followed by human epididymis protein 4 (HE4) and CA 72-4.
29 (30%), CA 72-4 (27%), AFP (22%), and Cyfra 21-1 (9%).
Keywords: cancer, gastric cancer, stomach cancer, carcinoembryonic antigen, alpha-fetoprotein, CEA, AFP, CA 50, CA 19-9, CA 195, CA 72-4, CA 125, CA 15-3, CA 27.
Clinical significance of the tumour markers CA 125 II and CA 72-4 in ovarian carcinoma.
We have selected a panel of tumour-associated antigens that includes the following markers: carcinoembryonic antigen (CEA), prostate specific antigen (PSA), alpha-fetoprotein (AFP), the carbohydrate antigens CA 19-9, CA 15-3, and CA 72-4, and ferritin.
Measurement of tumour-associated antigens: We divided the serum measurements into two groups, following the methods or assays used: IMX system (Abbott diagnostic division), a commercial microparticle enzymatic immunological assay used for measuring ferritin and PSA; and Enzymum-test (Boehringer Mannheim GmbH diagnostic division), a commercial immunoenzyme assay for CEA, CA 72-4, CA 15-3, AFP, and CA 19-9.
CA 125 II, CA 19-9 and CYFRA 21-1 are trademarks and CA 15-3 and CA 72-4 are registered trademarks of Fujirebio Diagnostics, Inc.
Stomach cancers showed 84% detection with Serum-RECAF(TM), a value unattainable by any other current blood test such as CA 19-9(TM), which detects 56% of stomach cancers with only 75% specificity and CA 72-4 (TM) which has a 51% sensitivity with 97% specificity.
The five tumor markers are: CA 19-9 and CA 72-4 for gastrointestinal cancers, Prostate Specific Antigen (PSA) for prostate cancer, CA 15-3 for breast cancer, and CA 125 for ovarian cancer.
Beacon has gained the rights to five of Centocor's tumor markers: CA 19-9 and CA 72-4 for gastrointestinal cancers, especially of the pancreas and stomach, Prostate Specific Antigen (PSA) for prostate cancer, CA 15-3 for breast cancer, and CA 125 for ovarian cancer.